COVID-19-induced granulomatosis with polyangiitis

Vijairam Selvaraj,1,2 Abdelmoniem Moustafa,1,2 Kwame Dapaah-Afriyie,1,2 Mark P Birkenbach3

SUMMARY
COVID-19 and granulomatosis with polyangiitis share many clinical and radiological features, making it challenging for clinicians to distinguish between the two. In this case report, we describe a patient who was diagnosed with COVID-19 in October 2020. One month later, she presented with persistent fatigue, shortness of breath and anaemia with worsening renal functions, found to have elevated antineutrophil cytoplasmic antibodies and antiproteinase 3 antibodies, and diagnosed with granulomatosis with polyangiitis.

BACKGROUND
Granulomatosis with polyangiitis (GPA) is a systemic disorder characterised by necrotising granulomatous vasculitis of small arteries and veins. Most patients present with respiratory symptoms such as cough, haemoptysis and dyspnoea. Renal involvement is only evident in 11%–20% at initial presentation, although glomerulonephritis develops in 77%–85% of the patients within the first 2 years of diagnosis.1 It may be challenging for clinicians to differentiate between GPA and COVID-19 as they share many clinical and radiological features.

CASE PRESENTATION
A 60-year-old woman with a history of diet-controlled diabetes mellitus, allergic rhinitis, and a diagnosis of COVID-19 4 weeks ago, presented to the hospital for a second time with a persistent cough, fatigue and poor appetite. She had been discharged 2 weeks prior for chest pain and shortness of breath, felt to be secondary to COVID-19-induced myopericarditis. She was treated with colchicine and ibuprofen, although she only took the medications for a few days and then was told to stop by her primary care provider due to a rise in her creatinine. Her creatinine was between 1.6 and 1.98 mg/dL, from a baseline of 0.72 mg/dL. Her home medications included lansoprazole and colchicine. She did not receive dexamethasone, tocilizumab or remdesivir for treatment of COVID-19 during her initial admission.

OUTCOME AND FOLLOW-UP
Her respiratory status along with her creatinine slowly improved over the course of her hospitalisation. She was discharged home after 4 weeks on a gradual prednisone taper along with atovaquone for pneumocystis jiroveci pneumonia (PJP) prophylaxis. Her creatinine remained stable at 2.18 mg/dL at 1-month follow-up.

DISCUSSION
Diagnostic criteria for GPA consist of clinical evidence of disease in at least two of three areas (upper airways, lung and kidney), and biopsy results showing disease in at least one and preferably two of these organ systems.2 Given the high prevalence of lung involvement, a CT scan is commonly performed in GPA. Significant chest CT scan findings are GGOs, consolidation, masses or nodules, which may cavitate.3 These features are non-specific and can be seen in other conditions, including...
COVID-19 pneumonia, PJP and lupus pneumonitis. Lung haemorrhage, seen in the disease’s active phase, may present as GGOs and consolidation in CT imaging. Patients with COVID-19 also sometimes present with acute kidney injury and haematuria due to rhabdomyolysis.3

As GPA and COVID-19 pneumonia share clinical and radiological features, diagnosis can be challenging. Clinicians are blindsighted by COVID-19, often missing conditions such as GPA.4 Despite being in a pandemic, clinicians must have a broad differential diagnosis, especially when the clinical picture is not consistent with COVID-19. Our patient had normal oxygen saturation and downtrending inflammatory markers, yet her renal function continued to deteriorate with persistent haematuria and proteinuria. Features such as irregularly walled cavities, ANCA antibodies and proteinuria also help in differentiating GPA from COVID-19.

The mechanism is unclear. Many patients with GPA initially present with upper respiratory symptoms. SARS-CoV-2 has high affinity for ACE2 receptors in the respiratory tract and can also directly invade the endothelial cells to cause vasculitis. In addition, myeloperoxidase (MPO) and PR3 enzymes are present on neutrophils, and autoantibodies to these enzymes can lead to pauci-immune glomerulonephritis. There is also evidence that neutrophil extracellular traps (NETs) serve as a source of autoantigens presenting MPO and PR3 to the immune system. NETs have been noticed on kidney biopsy samples of patients with ANCA-associated vasculitis and could be involved in the pathogenesis.5–7

The diagnosis of GPA is often overlooked and delayed due to a wide range of clinical presentations. It is extremely rare to develop GPA after COVID-19 infection.8 Another case report described a patient diagnosed with GPA with positive COVID-19 IgM and negative PCR test.9 However, in our case, GPA developed 4 weeks after true COVID-19 infection confirmed by positive SARS-CoV-2 PCR test. Treatment of GPA involves a multidisciplinary approach and usually includes corticosteroids, rituximab or cyclophosphamide.10

In conclusion, early diagnosis of GPA requires a high index of suspicion in all patients, especially in atypical presentation cases. This case report suggests association between COVID-19 infection and new-onset GPA. Prompt diagnosis and appropriate management of GPA in patients previously infected or coinfected with COVID-19 are essential to reduce morbidity and mortality.

Learning points

► Distinguishing between granulomatosis with polyangiitis (GPA) and COVID-19 is difficult given similarity in clinical and radiological features.
► Features such as irregularly walled cavities, antineutrophil cytoplasmic antibodies and proteinuria help in differentiating GPA from COVID-19.
► Physicians must have a high index of suspicion, especially in patients with atypical presentation to start immunosuppressive therapy.
REFERENCES

Copyright 2021 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit https://www.bmj.com/company/products-services/rights-and-licensing/permissions/

Become a Fellow of BMJ Case Reports today and you can:
► Submit as many cases as you like
► Enjoy fast sympathetic peer review and rapid publication of accepted articles
► Access all the published articles
► Re-use any of the published material for personal use and teaching without further permission

Customer Service
If you have any further queries about your subscription, please contact our customer services team on +44 (0) 207111 1105 or via email at support@bmj.com.

Visit casereports.bmj.com for more articles like this and to become a Fellow.